The OK04 trial was a study of induction-maintenance therapy using lopinavir (LPV)/RTV alone for maintenance therapy compared with continuous therapy with LPV/ RTV plus two nucleoside reverse transcriptase inhibitors (NRTIs) [22, 23] A total of 205 patients were randomized to either LPV/RTV alone maintenance therapy (n=103) or continued standard therapy (n=102). After 48 weeks, 11 patients in the LPV/RTV alone arm developed virological rebound compared to 4 in the standard therapy arm. Major protease resistance mutations were identified by population genotype at virological rebound in three subjects, two in the LPV/RTV alone arm and one in the standard therapy arm [22] . NRTI resistance was identified in one subject from each treatment arm [22] . The prevalence of low frequency PI-resistant variants was not examined. Therefore, we developed a single genome
Current antiretroviral therapy can extend the life expectancy of HIV-1-infected individuals for 35 to 49 years [1] . Despite this benefit, medication side effects, emergence of drug resistance and the high cost of therapy pose significant challenges in maintaining viral suppression [2] [3] [4] [5] [6] . Several strategies to minimize antiretroviral drug exposure and improve medication compliance have been evaluated with mixed results [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Inductionmaintenance strategies with ritonavir (RTV)-boosted protease inhibitors (PIs) have shown promise [19] , but loss of virological control and emergence of PI resistance have been common concerns about this approach [21] .
The OK04 trial was a study of induction-maintenance therapy using lopinavir (LPV)/RTV alone for maintenance therapy compared with continuous therapy with LPV/ RTV plus two nucleoside reverse transcriptase inhibitors (NRTIs) [22, 23] A total of 205 patients were randomized to either LPV/RTV alone maintenance therapy (n=103) or continued standard therapy (n=102). After 48 weeks, 11 patients in the LPV/RTV alone arm developed virological rebound compared to 4 in the standard therapy arm. Major protease resistance mutations were identified by population genotype at virological rebound in three subjects, two in the LPV/RTV alone arm and one in the standard therapy arm [22] . NRTI resistance was identified in one subject from each treatment arm [22] . The prevalence of low frequency PI-resistant variants was not examined. Therefore, we developed a single genome
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Methods

Samples
Plasma samples from 15 subjects experiencing virological rebound with HIV-1 RNA>500 copies/ml during the OK04 study were obtained for single genome sequencing. Four samples were from the standard therapy arm and 11 from the LPV/RTV alone arm.
Single genome sequencing of gag and protease An SGS method was developed for gag and protease [24] . Briefly, 1-2 ml samples of plasma were centrifuged at 16,000×g for 1 h at 4°C and the pellet was extracted with guanidinium isothiocyanate, followed by isopropanol precipitation, ethanol washes and resuspension in 5 mM Tris-HCL as described [24] . Reverse transcriptase (RT) mix (Superscript II 2 U/ul, RNaseOUT 0.4 U/ul, MgCl 2 0.02 mM/ul, 10×RT buffer and RNase free water) was added to the viral RNA for complementary DNA (cDNA) synthesis using the 2445 reverse sequencing primer (5′-agtcttcatctaagggaact-3′). Serial dilutions were performed of the cDNA products and plated for nested PCR reactions amplifying codon 100 of matrix to codon 14 of RT, for final read length. Nested primers were constructed to bind to conserved regions of HIV-1 gag: 495 forward (5′-tcagaaggctgtagacaaa-3′) and 578 forward (5′-agtagcaaccctctattgt-3′) and conserved areas of HIV-1 pol: 2445 reverse (5′-agtcttcatctaagggaact-3′) and 2343 reverse (5′-tcccagaagtcttgagttc-3′). By Poisson distribution, cDNA dilutions yielding approximately 30% positive reactions were considered to be derived from single cDNA molecules and were sequenced. Single sequences from each sample were aligned and compared to HIV-1 subtype B consensus sequence using Sequencher software version 4.8 (Gene Codes, Ann Arbor, MI, USA). The IAS-USA 2009 resistance mutations table was used to identify major and minor PI resistance mutations in protease. Gag and transframe protein (TFP)-p6 pol resistance mutations at cleavage sites (CS) and non-cleavage sites (NCS) identified in at least two prior publications are reported here [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] .
Data analysis
Analysis of at least 45 sequences per sample was planned to achieve detection of 90% of minor variants comprising 5% of the population. All comparisons between the LPV/RTV alone and standard therapy arms were performed with non-parametric tests, including Wilcoxon rank-sum, Mann-Whitney U, and median tests for comparisons between treatment arms of the number of mutations in gag and protease. All P-values are two sided; P-values of 0.05 or lower were considered statistically significant.
Results
Plasma samples from 15 patients at virological rebound were analysed by gag and protease SGS. Plasma HIV-1 RNA levels ranged from 524 to 72,300 copies/ml. Stored samples with 1-2 ml of plasma were available for testing from the original OK04 study. In 4 of 11 subjects samples from the LPV/RTV alone arm, the samples yielded ≤6 sequences for SGS analysis after repeated testing, possibly due to high lipid content and/ or low HIV-1 RNA copies/ml. Sequences were obtained from 13 of 15 samples. A total of 521 sequences were analysed with a mean of 35 (median 46) sequences per patient sample (range 4-47).
Resistance mutations in protease
Standard population genotype performed during the OK04 study detected major PI resistance mutations in protease in one subject receiving two NRTI plus LPV/ RTV (I54V/V82A) and in two subjects on LPV/RTV alone (M46I and M46I/I54V/V82A). SGS detected each of these major PI resistance mutations in protease identified by population genotype (Table 1 ). In addition, SGS identified primary PI resistance mutations in protease in samples from five subjects that were not detected by standard genotype: three in the standard therapy arm and two in the LPV/RTV alone arm. Three of the four subjects with virological rebound on standard therapy had M46I mutations detected by SGS, but not by standard genotype. Two of these patients had no primary PI resistance detected by standard genotype. Two subjects in the LPV/RTV alone arm had additional PI resistance mutations detected by SGS: M46I/L was identified in one patient and V82A in the other. Overall, 3 of 4 patients with virological rebound in the standard therapy arm had major PI resistance mutations in protease compared with 3 of 11 patients in the LPV/RTV alone arm (P=0.10). Minor resistance mutations in protease were identified in all samples tested and with no significant difference in the median number of mutations per sample, with 3.0 versus 3.5 mutations/sample in the LPV/RTV alone and standard therapy arms, respectively (P=0.23).
Mutations at gag cleavage and non-cleavage sites
We identified mutations by SGS in gag-CS and gag-NCS in the gag reading frame and in TFP-p6 pol regions in the pol reading frame (Table 2 ) and compared their frequency between treatment arms. The most frequently detected gag-CS mutations were V128A/S (two patients), S373P/A (five patients), T375N/A/S (seven patients), I376V (two patients), R380K/G (seven 
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patients) and S451N (two patients). The commonly reported L449P mutation [28] [29] [30] [31] 33, 40, 42] was only identified in one subject (Table 3) . Several gag-NCS mutations associated with PI resistance were also detected at virological rebound including K113Q/E (three patients), H219Q (four patients), I389T/M/P (nine patients), V390I (two patients), T456S (two patients), R479V/T/K (six patients) and A487S (two patients). Overall, there were no significant differences between the LPV/RTV alone and standard therapy 
arms in the median number of PI resistance mutations at gag-CS (3.0 versus 2.5, respectively; P=0.83) and gag-NCS (21.0 versus 16.5, respectively; P=0.71). All mutations at gag sites that were identified in ≥15% of the sequences/patient and in multiple patients are listed in the Table 3 . All listed gag mutations in Table 3 were found at higher frequency than in the sequences obtained from the Los Alamos HIV treatment-naive database. Clinical significance of these mutations is unknown as emergence during virological rebound could not be confirmed without available baseline samples.
Mutations in TFP-p6 pol at cleavage and noncleavage sites
Each of the patients analysed by SGS had the L9P mutation in the TFP-p6 CS and 11 of 13 patients had the N55D/V/S mutation in the p6-pro cleavage sites ( Table 2 ). D5N (6) and K12E (5) mutations in the TFP-p6 CS were also frequently detected. In the TFP-p6 pol region, no known PI resistance mutations were identified at NCS. There were no significant differences found between treatment arms in the median number of PI resistance-associated mutations in the TFP-p6 pol region at CS (3.0 versus 4.0; P=0.6) and for other mutations not previously associated with PI resistance at non-cleavage sites (4.0 versus 4.0; P=0.83).
Linkage of mutations
We examined the linkage between PI resistance mutations in gag, p6-pol and protease. Major protease PI resistance mutations identified only by SGS were linked on the same sequence with major protease resistance identified by standard population genotype.
Sequences containing major protease PI resistance mutations were always linked to gag and TFP-p6 mutations. Otherwise, there was no consistent pattern of linkage between gag, TFP-p6 mutations and the major protease PI resistance mutations.
Discussion
This is the first comparative analysis using SGS of PI resistance mutations in protease and gag at virological rebound from a randomized trial of treatment simplification to LPV/RTV alone versus continued standard therapy. Major PI resistance mutations that were missed by standard genotype were present on average in 2.6% of the single sequences obtained. SGS analyses revealed major PI resistance mutations in 3 of 11 subjects with virological rebound on LPV/RTV alone compared with 3 out 4 with rebound on standard therapy. Thus, major PI resistance mutations in protease were not detected more frequently at virological rebound in patients on LPV/RTV alone. These findings are in agreement with previous reports of standard population genotype analysis showing similar frequencies of major PI resistance in protease with virological rebound of simplified versus standard therapy [44] [45] [46] [47] [48] . Specifically, in randomized clinical trials by Singh et al. and Nunes et al. only one patient from each of the simplified therapy arms with a RTV-boosted PI had virological failure without major PI resistance mutations in protease identified in either patient [45, 46, 49] . The greater sensitivity of SGS for PI resistance mutations in the current study provides additional reassurance that resistance is not more frequent with failure of maintenance therapy with a RTV-boosted PI alone.
In the current study, analysis of gag sequences from matrix to p6, including both CS and NCS, revealed similar frequencies of known gag-NCS and gag-CS mutations associated with PI resistance in both treatment arms. The LPV/RTV alone arm had a higher median number of gag-NCS mutations than the standard therapy arm, but this difference was not statistically significant (P=0.42). The most common PI-associated resistance mutations in gag-NCS were I389T/M/P and R479V/T/K. Only mutations at gag-NCS codon 389 showed a trend towards higher frequency in the LPV/ RTV alone arm (P=0.08). Analysis of mutations in CS in the TFP-p6 pol region also revealed similar frequencies of PI resistance-associated mutations in both treatment arms.
Overall, there were no significant differences between the frequencies of known PI resistance mutations in gag-CS, gag-NCS and in the TFP-p6 pol region at virological rebound in the LPV/RTV alone and standard therapy arms, again suggesting that simplified maintenance therapy with LPV/RTV does not increase the risk of PI resistance. Sequences containing major PI resistance mutations in protease were present with mutations in both gag and TFP-p6 pol in all sequences examined. Otherwise, no specific patterns of linkage between specific mutations in protease, gag and TFP-p6 pol could be identified.
Our study is limited by the small number of patients with virological rebound analysed, restricting power to detect small differences in the frequency of resistance mutation between the two treatment arms. Nevertheless, no trends were observed toward more frequent major PI resistance mutations with LPV/RTV maintenance therapy. In addition, the OK04 trial design required that all subjects entering the study had HIV-1 RNA below the limit of detection; hence, samples from study entry could not be sequenced to determine whether mutations at virological rebound had been selected by the therapies in the OK04 trial. However, our study does provide an in-depth analysis of the presence of PI resistance mutations beyond that provided by standard population genotype analysis.
In summary, the detailed sequence analyses performed in this study show no increase in the frequency of PI resistance mutations in gag or protease with virological rebound of simplified therapy with LPV/RTV alone compared with continued standard therapy with two NRTIs and LPV/RTV. In addition, simplified therapy with LPV/RTV alone has the advantage of reducing exposure to NRTI resistance. These favourable features support further consideration of simplified maintenance therapy with RTV-boosted PIs.
